Elagolix placebo

DRUG4 trials

Sponsors

AbbVie, Qilu Pharmaceutical (Hainan) Co., Ltd., Nanjing Chia-tai Tianqing Pharmaceutical

Conditions

EndometriosisHeavy Menstrual BleedingHeavy Uterine BleedingUterine Fibroids

Phase 2

Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

CompletedNCT01817530

AbbVieHeavy Uterine Bleeding, Uterine Fibroids

Start: 2013-04-08End: 2015-12-31Updated: 2020-07-21

Phase 3

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

CompletedNCT03271489

AbbVieHeavy Menstrual Bleeding, Uterine Fibroids

Start: 2017-09-13End: 2024-06-28Updated: 2025-07-22

A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain

Qilu Pharmaceutical (Hainan) Co., Ltd.Endometriosis

Start: 2022-09-04End: 2024-02-29Target: 336Updated: 2022-12-13

A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain

CompletedNCT06076486

Nanjing Chia-tai Tianqing PharmaceuticalEndometriosis

Start: 2023-09-14End: 2025-04-02Updated: 2025-09-23

Related Papers

Bone mineral density with elagolix plus add-back therapy in women with heavy menstrual bleeding and uterine fibroids: open-label and post-treatment results of a 60-month phase 3 trial.

2025-10-11

Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas

Obstetrics and Gynecology2018-10-1066 citations

Endometrial Evaluation in Elagolix-Treated Women With Uterine Fibroids and Heavy Menstrual Bleeding [25G]

Obstetrics and Gynecology2018-04-27